Key Highlights

  • The Felix System has received required product registration in Turkey, recorded on the country's national Product Tracking System, enabling commercial sales under the ITL distribution agreement.
  • The first commercial sale in Turkey has been completed, comprising 100 Felix cartridges and two consoles, providing an installed platform for clinic demonstrations and further sales.
  • A 2024 peer-reviewed national study identified 165 ART centres operating in Turkey, with the country estimated to undertake approximately 75,000 assisted reproductive technology treatment cycles annually.
  • Before the Turkish order, ITL had placed orders for 1,800 Felix cartridges, representing 72% of its 2,500-cartridge territory-wide minimum annual purchase commitment, in under two quarters.

Turkey Registration and Initial Sale

Memphasys Limited (ASX:MEM) has advised that the Felix System has received the required product registration in Turkey, enabling its Middle East and North Africa distribution partner, International Technical Legacy (ITL), to commence commercial sales of the Felix cartridge and console into the Turkish market through its local distribution network. The registration is recorded on Turkey's national Product Tracking System (ÜTS).

Turkey was added to the ITL distribution territory following CE Mark approval and the expansion of the agreement in September 2025. The first commercial sale in Turkey has now been completed, comprising 100 Felix cartridges and two consoles, providing an installed platform from which the local distributor can undertake clinic demonstrations, education and customer conversion activities.

Distributor Training and Market Development

Memphasys has completed hands-on product training with ITL's in-country distribution partner, intended to equip the local team to introduce Felix to IVF clinics and support the technical and workflow discussions central to adoption of new laboratory technologies. The company and its local distribution partner will now expand market-development activity in Turkey through further clinic engagement, product demonstrations and training.

The company expects these activities to support additional cartridge and console sales over coming quarters, though it has noted that the timing and value of future orders will depend on clinic adoption and purchasing decisions.

Turkish Market Opportunity

Turkey has a large and established assisted-reproduction sector. A peer-reviewed national study published in 2024 identified 165 ART centres operating in the country, with Turkey estimated to undertake approximately 75,000 assisted reproductive technology treatment cycles annually.

A/Prof Hassan Bakos, Memphasys Director of Clinical Partnerships and Growth, said regulatory registration in Turkey is an important commercial enabler for Felix under the ITL agreement, and that the initial sale and distributor training provide a practical starting point in a large, established IVF market.

ITL Agreement Context

ITL is Memphasys' exclusive commercial partner for the Middle East and North Africa under a five-year agreement. Prior to the Turkish order, ITL had placed orders for 1,800 Felix cartridges, representing 72% of its 2,500-cartridge territory-wide minimum annual purchase commitment, achieved in less than two quarters.

Conclusion

Memphasys has secured product registration for its Felix System in Turkey, enabling its ITL distribution partner to commence commercial sales with an initial order of 100 cartridges and two consoles, positioning the company to pursue further growth in a market with 165 established ART centres and approximately 75,000 annual treatment cycles, while its broader ITL territory has already reached 72% of its annual minimum purchase commitment.